Zhonghua Nei Ke Za Zhi · Nov 1, 2026

Hemolytic anemia due to G6PD deficiency induced by glycemic fluctuation in a patient with type 2 diabetes mellitus: a case report and literature review

By Wang YB, Lin SS, Liu B et al.

This study reported a case of type 2 diabetes mellitus with glucose-6-phosphate dehydrogenase (G6PD) deficiency admitted to Beijing Friendship Hospital, Capital Medical University in August 2022. The clinical characteristics, diagnosis, and treatment were retrospectively analyzed, and the literature was reviewed. The patient was a 72-year-old male admitted for marked hyperglycemia without diabetic ketoacidosis. He received intensive glucose-lowering therapy with insulin plus metformin, acarbose, and dapagliflozin. On day 6, after blood glucose had markedly improved, he developed fatigue and scleral icterus. Laboratory tests showed progressively increased indirect bilirubin (11.18➝54.57 μmol/L) and decreased hemoglobin (124➝81 g/L). Coombs test and autoantibody screening were negative. Suspected drugs were discontinued; bilirubin gradually normalized and hemoglobin recovered. G6PD activity was significantly reduced (197 U/L, reference range >1 300 U/L), and genetic testing revealed a hemizygous mutation in G6PD Exon 12: c.1478G>A. A review of the literature showed that of 11 patients with type 2 diabetes mellitus (including the present case) who developed hemolytic anemia during treatment, most had hyperglycemia, rapid short-term glycemic fluctuations (7 cases), and G6PD deficiency (9 cases), and the mechanism mainly involved the rapid improvement of blood glucose itself. This case suggests that when unexplained anemia or jaundice occurs during rapid glycemic improvement in patients with type 2 diabetes mellitus, G6PD deficiency should be considered.

doi.org/10.3760/cma.j.cn112138-20260727-00441PubMed 43035269Interventions

AgingResearch.News